Using macaques to guide the design of an HIV-1 vaccine
Reverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine Design
['FUNDING_R01'] · UNIVERSITY OF PENNSYLVANIA · NIH-10764910
This study is looking at how certain viruses in monkeys can help scientists figure out what kind of immune responses we need to create a strong HIV vaccine for people. By understanding how these monkeys develop protective antibodies, researchers hope to design a vaccine that works well for humans.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10764910 on ClinicalTrials.gov |
What this research studies
This research investigates how simian-human immunodeficiency viruses (SHIVs) in rhesus macaques can help identify the immune responses necessary for developing an effective HIV-1 vaccine. By studying the patterns of antibody development in these macaques, researchers aim to understand the molecular mechanisms that lead to broadly neutralizing antibodies (bNAbs) against HIV-1. The approach involves isolating specific antibodies and analyzing their interactions with the virus to inform vaccine design. This could provide valuable insights into creating a vaccine that elicits similar protective responses in humans.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research would be individuals at high risk for HIV infection who are seeking preventive measures.
Not a fit: Patients who are already living with HIV and are not seeking a vaccine would not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a more effective HIV-1 vaccine, potentially reducing the incidence of HIV infections.
How similar studies have performed: Previous research has shown promise in using animal models to inform vaccine design, indicating that this approach could be effective.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHAW, GEORGE M — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: SHAW, GEORGE M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.